{"publication_id":"faf58aa1-0279-46d8-a52f-a9e3f585c07c","content_hash":"sha256:4ee5fe3b76812702c33b3e7746825ac1ffb57b281aa752dd7e67ea37b15e92b4","nodes":[{"id":"faf58aa1-0279-46d8-a52f-a9e3f585c07c","type":"publication","title":"Discontinuation-driven weight regain and lean mass dynamics: Implications for sustained metabolic healthspan with GLP-1 RAs"},{"id":"claim_1","type":"claim","text":"The direct receipts support a narrow working claim: The incidence of thyroid cancer in semaglutide-treated patients was less than 1%, suggesting no significant risk; Serious adverse events varied from 7% to 25.2%, highlighting the need for vigilant patient monitoring. The context receipts provide source breadth and boundary checks, not independent confirmation of the lead claim."},{"id":"claim_2","type":"claim","text":"Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication."},{"id":"claim_3","type":"claim","text":"Bounded signal: the useful signal is narrower than the topic label. The lead receipts support the core claim, while the added A/B context receipts define where that claim may generalize, fail, or need a separate extraction."},{"id":"claim_4","type":"claim","text":"`fact_id=139252` (`A_core`) — The incidence of thyroid cancer in semaglutide-treated patients was less than 1%, suggesting no significant risk. doi=10.3390/ijms25084346"},{"id":"claim_5","type":"claim","text":"_Boundary evidence only; these receipts broaden source context but do not independently prove the lead claim._"},{"id":"source_1","type":"source","study":"Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review","year":2024,"doi":"10.3390/ijms25084346","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_2","type":"source","study":"Efficacy and safety of once‐weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus—A systematic review and meta‐analysis of randomized controlled trials","year":2024,"doi":"10.1111/obr.13792","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_3","type":"source","study":"Efficacy and Safety of Tirzepatide in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Phase II/III Trials","year":2021,"doi":"10.3390/ph14100991","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_4","type":"source","study":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","year":2022,"doi":"10.1038/s41591-022-02026-4","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_5","type":"source","study":"Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity The STEP 3 Randomized Clinical Trial","year":2021,"doi":null,"url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_6","type":"source","study":"Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial","year":2024,"doi":"10.1038/s41591-024-02996-7","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"}],"edges":[{"from":"faf58aa1-0279-46d8-a52f-a9e3f585c07c","to":"claim_1","type":"contains_claim"},{"from":"faf58aa1-0279-46d8-a52f-a9e3f585c07c","to":"claim_2","type":"contains_claim"},{"from":"faf58aa1-0279-46d8-a52f-a9e3f585c07c","to":"claim_3","type":"contains_claim"},{"from":"faf58aa1-0279-46d8-a52f-a9e3f585c07c","to":"claim_4","type":"contains_claim"},{"from":"faf58aa1-0279-46d8-a52f-a9e3f585c07c","to":"claim_5","type":"contains_claim"}],"screening":{"identified":6,"screened":6,"excluded":0,"included":6,"included_or_retained":6,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"6 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]}}